NCT04797650

Study to Evaluate the Efficacy and Safety of CTP-543 in Adults With Moderate to Severe Alopecia Areata (THRIVE-AA2)

A Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of CTP-543 in Adult Patients With Moderate to Severe Alopecia Areata

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 517 (actual)
• Sponsor: Concert Pharmaceuticals · Industry
• Sex: All
• Age: 18 Years – 65 Years
• Healthy volunteers: Not accepted

Summary

This study evaluates the safety and effectiveness of an investigational study drug (called CTP-543) in adults (18 years and older) who have 50% or greater scalp hair loss.

Conditions

• Alopecia Areata

Interventions

Type	Name	Description
DRUG	CTP-543 matching placebo	Administered as tablets.
DRUG	CTP-543	Administered as tablets.

Timeline

• Start date: 2021-06-10
• Primary completion: 2022-06-08
• Completion: 2022-06-29
• First posted: 2021-03-15
• Last updated: 2023-07-03
• Results posted: 2023-07-03

Locations

63 sites across 7 countries: United States, Canada, France, Germany, Hungary, Poland, Spain

Regulatory

• FDA-regulated drug study